SCHEMBL775253

SCHEMBL775253

CCCSc1cnc2ccc(OC)cc2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.46
CYP2E1 P05181 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C8 P10632 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2B6 P20813 2/20 0.46
CYP2C19 P33261 2/20 0.46
NMT1 P30419 2/20 0.42
THRB P10828 1/20 0.41
EGFR P00533 3/20 0.40
DYRK3 O43781 1/20 0.40
CLK1 P49759 1/20 0.40
CLK2 P49760 1/20 0.40
CLK3 P49761 1/20 0.40
GSK3B P49841 1/20 0.40
DYRK1A Q13627 1/20 0.40
HASPIN Q8TF76 1/20 0.40
DYRK2 Q92630 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL773566 0.84 CYP1A2 (0.46) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6
SCHEMBL775697 0.77 ACHE (0.42) CYP1A2CYP3A4CYP2D6CYP2C19EGFR
SCHEMBL773988 0.76 ACHE (0.41) EGFRMAPT
SCHEMBL5746994 0.73 KDM4E (0.46) CYP1A2CYP3A4CYP2C19EGFRGABRA1
SCHEMBL31384368 0.73 LMNA (0.43) EGFRGABRA1GABRG2GABRB3GABRA5
SCHEMBL5706839 0.73 CYP17A1 (0.44) EGFRGABRA1GABRG2GABRB3GABRA5
SCHEMBL13652287 0.73 LMNA (0.43) EGFRGABRA1GABRG2GABRB3GABRA5
SCHEMBL9725738 0.73 LMNA (0.48) CYP2C19NMT1THRBMAPTSMN1; SMN2
SCHEMBL28160305 0.72 HTR1A (0.42) CYP1A2EGFRGABRA1GABRG2GABRB3
SCHEMBL2554288 0.72 DYRK3 (0.72) CYP1A2CYP2E1CYP3A4CYP2C8CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071505-A1 SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-03-22 US disclosed
WO-2011022216-A1 SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS HIGH POINT PHARMACEUTICALS, LLC (US) 2011-02-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071505-A1 SUBSTITUTED PYRIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE TO TREAT OXIDATIVE STRESS HMOX2, HMOX1, MPO CYP1A2 174/4885CYP2E1 37/4885CYP3A4 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.